Overview

Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -

Status:
Completed
Trial end date:
2017-10-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of sodium risedronate tablets administered once daily (one tablet per dose) in patients with osseous Paget's disease for 48 weeks from baseline in daily medical practice.
Details
Lead Sponsor:
Takeda
Treatments:
Etidronic Acid
Risedronate Sodium
Risedronic Acid